Literature DB >> 26908493

Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis.

R Nicolai1, E Cortis2, L Ravà3, C Bracaglia1, M Pardeo1, A Insalaco1, P S Buonuomo4, A E Tozzi3, F De Benedetti1.   

Abstract

Incidence rates for varicella and herpes zoster were similar in patients with juvenile idiopathic arthritis receiving etanercept/methotrexate (n = 85, 184.9 patient-years [PY]) or methotrexate alone (n = 71, 199.4 PY); no complicated varicella or herpes zoster cases were reported; herpes labialis incidence was higher in patients receiving etanercept/methotrexate versus methotrexate alone (0.38 vs. 0.24 PY).
© The Author 2014. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  etanercept; herpes simplex virus; juvenile idiopathic arthritis; varicella zoster virus

Mesh：

Substances：

Year:  2014        PMID： 26908493     DOI： 10.1093/jpids/piu078

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  1 in total

1.  Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee.

Authors:  Gabriella Giancane; Joost F Swart; Elio Castagnola; Andreas H Groll; Gerd Horneff; Hans-Iko Huppertz; Daniel J Lovell; Tom Wolfs; Troels Herlin; Pavla Dolezalova; Helga Sanner; Gordana Susic; Flavio Sztajnbok; Despoina Maritsi; Tamas Constantin; Veronika Vargova; Sujata Sawhney; Marite Rygg; Sheila K Oliveira; Marco Cattalini; Francesca Bovis; Francesca Bagnasco; Angela Pistorio; Alberto Martini; Nico Wulffraat; Nicolino Ruperto
Journal:  Arthritis Res Ther       Date:  2020-04-07       Impact factor: 5.156
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.